BLIS Technologies Ltd
NZX:BLT

Watchlist Manager
BLIS Technologies Ltd Logo
BLIS Technologies Ltd
NZX:BLT
Watchlist
Price: 0.017 NZD -5.56% Market Closed
Market Cap: 21.7m NZD

Relative Value

The Relative Value of one BLT stock under the Base Case scenario is 0.011 NZD. Compared to the current market price of 0.017 NZD, BLIS Technologies Ltd is Overvalued by 38%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

BLT Relative Value
Base Case
0.011 NZD
Overvaluation 38%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
71
vs Industry
63
Median 3Y
2.3
Median 5Y
4.8
Industry
2.5
vs History
34
vs Industry
36
Median 3Y
-18.3
Median 5Y
11.6
Industry
21.6
vs History
53
vs Industry
38
Median 3Y
11.9
Median 5Y
19.4
Industry
16.7
vs History
25
vs Industry
23
Median 3Y
17.2
Median 5Y
16
Industry
24
vs History
73
vs Industry
48
Median 3Y
2.3
Median 5Y
3.2
Industry
2.2
vs History
73
vs Industry
78
Median 3Y
1.5
Median 5Y
3.8
Industry
2.7
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
5.3
vs History
25
vs Industry
45
Median 3Y
-14.5
Median 5Y
5.6
Industry
12.9
vs History
25
vs Industry
45
Median 3Y
-14.5
Median 5Y
5.6
Industry
16.3
vs History
53
vs Industry
48
Median 3Y
6.9
Median 5Y
12.7
Industry
15.2
vs History
44
vs Industry
35
Median 3Y
9.5
Median 5Y
9.5
Industry
17.7
vs History
53
vs Industry
25
Median 3Y
3.9
Median 5Y
5.6
Industry
1.9

Multiples Across Competitors

BLT Competitors Multiples
BLIS Technologies Ltd Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
NZ
BLIS Technologies Ltd
NZX:BLT
21.7m NZD 1.7 26 25.4 25.4
US
Eli Lilly and Co
NYSE:LLY
751.6B USD 15.3 67.7 36.3 39.7
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
377.4B USD 4.2 17.3 12.6 16.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.9T DKK 6.4 18.6 12.9 14.8
CH
Roche Holding AG
SIX:ROG
204.3B CHF 3.4 24.7 9.3 10.9
CH
Novartis AG
SIX:NOVN
188.5B CHF 4.4 18.4 10.8 14.5
UK
AstraZeneca PLC
LSE:AZN
162B GBP 4 28.2 130.7 197.2
US
Merck & Co Inc
NYSE:MRK
209.7B USD 3.3 12 8.9 10.8
IE
Endo International PLC
LSE:0Y5F
184.8B USD 79.7 -63.2 294 737.3
US
Pfizer Inc
NYSE:PFE
145.8B USD 2.3 18.5 7.8 11
P/E Multiple
Earnings Growth PEG
NZ
BLIS Technologies Ltd
NZX:BLT
Average P/E: 25.7
26
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
67.7
49%
1.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17.3
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
18.6
18%
1
CH
Roche Holding AG
SIX:ROG
24.7
32%
0.8
CH
Novartis AG
SIX:NOVN
18.4
17%
1.1
UK
AstraZeneca PLC
LSE:AZN
28.2
36%
0.8
US
Merck & Co Inc
NYSE:MRK
12
17%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -63.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
18.5
30%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
NZ
BLIS Technologies Ltd
NZX:BLT
Average EV/EBITDA: 399.6
25.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
36.3
30%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.6
7%
1.8
DK
Novo Nordisk A/S
CSE:NOVO B
12.9
13%
1
CH
Roche Holding AG
SIX:ROG
9.3
5%
1.9
CH
Novartis AG
SIX:NOVN
10.8
5%
2.2
UK
AstraZeneca PLC
LSE:AZN
130.7
10%
13.1
US
Merck & Co Inc
NYSE:MRK
8.9
8%
1.1
IE
E
Endo International PLC
LSE:0Y5F
294
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.8
2%
3.9
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
NZ
BLIS Technologies Ltd
NZX:BLT
Average EV/EBIT: 1 707.3
25.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39.7
32%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.6
13%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
14.8
14%
1.1
CH
Roche Holding AG
SIX:ROG
10.9
6%
1.8
CH
Novartis AG
SIX:NOVN
14.5
10%
1.5
UK
AstraZeneca PLC
LSE:AZN
197.2
23%
8.6
US
Merck & Co Inc
NYSE:MRK
10.8
11%
1
IE
E
Endo International PLC
LSE:0Y5F
737.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
11
10%
1.1